JPWO2019232126A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019232126A5
JPWO2019232126A5 JP2020566737A JP2020566737A JPWO2019232126A5 JP WO2019232126 A5 JPWO2019232126 A5 JP WO2019232126A5 JP 2020566737 A JP2020566737 A JP 2020566737A JP 2020566737 A JP2020566737 A JP 2020566737A JP WO2019232126 A5 JPWO2019232126 A5 JP WO2019232126A5
Authority
JP
Japan
Prior art keywords
composition
subject
sepiapterin
food
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020566737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525746A (ja
JP2021525746A5 (https=
JP7547215B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/034515 external-priority patent/WO2019232126A1/en
Publication of JP2021525746A publication Critical patent/JP2021525746A/ja
Publication of JPWO2019232126A5 publication Critical patent/JPWO2019232126A5/ja
Publication of JP2021525746A5 publication Critical patent/JP2021525746A5/ja
Priority to JP2024146283A priority Critical patent/JP2024178188A/ja
Application granted granted Critical
Publication of JP7547215B2 publication Critical patent/JP7547215B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566737A 2018-05-30 2019-05-30 テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法 Active JP7547215B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024146283A JP2024178188A (ja) 2018-05-30 2024-08-28 テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862677926P 2018-05-30 2018-05-30
US62/677,926 2018-05-30
US201862771397P 2018-11-26 2018-11-26
US62/771,397 2018-11-26
US201962822365P 2019-03-22 2019-03-22
US62/822,365 2019-03-22
GC201937662 2019-05-28
GC2019-37662 2019-05-28
PCT/US2019/034515 WO2019232126A1 (en) 2018-05-30 2019-05-30 Compositions and methods for increasing tetrahydrobiopterin plasma exposure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024146283A Division JP2024178188A (ja) 2018-05-30 2024-08-28 テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法

Publications (4)

Publication Number Publication Date
JP2021525746A JP2021525746A (ja) 2021-09-27
JPWO2019232126A5 true JPWO2019232126A5 (https=) 2022-06-03
JP2021525746A5 JP2021525746A5 (https=) 2022-06-03
JP7547215B2 JP7547215B2 (ja) 2024-09-09

Family

ID=68699016

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566737A Active JP7547215B2 (ja) 2018-05-30 2019-05-30 テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法
JP2024146283A Pending JP2024178188A (ja) 2018-05-30 2024-08-28 テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024146283A Pending JP2024178188A (ja) 2018-05-30 2024-08-28 テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法

Country Status (10)

Country Link
US (2) US12257252B2 (https=)
EP (1) EP3801534B1 (https=)
JP (2) JP7547215B2 (https=)
CN (1) CN112654356A (https=)
BR (1) BR112020024329A2 (https=)
CA (1) CA3102105A1 (https=)
DK (1) DK3801534T3 (https=)
FI (1) FI3801534T3 (https=)
MX (1) MX2020012980A (https=)
WO (1) WO2019232126A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
EP3801536B1 (en) * 2018-05-30 2024-07-17 PTC Therapeutics MP, Inc. Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
CN112654356A (zh) 2018-05-30 2021-04-13 Ptc医疗Mp公司 增加四氢生物蝶呤血浆暴露的组合物和方法
CA3165636A1 (en) * 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
US12298026B1 (en) 2021-04-12 2025-05-13 W. L. Gore & Associates, Inc. Latent energy transfer laminate for plate pack core

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
CA2228970A1 (en) 1995-08-18 1997-02-27 Donald W. Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
EP1696877A4 (en) 2003-11-13 2010-06-09 Gen Hospital Corp PROCESS FOR PAIN TREATMENT
US7732599B2 (en) 2003-11-17 2010-06-08 Biomarin Pharmaceutical Inc. Process for preparing tetrahydrobiopterin and analogs of tetrahydrobiopterin
CA2678125C (en) 2003-11-17 2014-10-14 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
KR20070005550A (ko) 2003-11-17 2007-01-10 바이오마린 파머수티컬 인크. 대사 장애 치료를 위한 조성물 및 방법
WO2006055511A2 (en) 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
CA2588994A1 (en) 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
US7582799B2 (en) 2005-04-28 2009-09-01 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
WO2008128049A2 (en) 2007-04-11 2008-10-23 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
US20110144117A1 (en) 2008-08-12 2011-06-16 Orpha Swiss Gmbh Pharmaceutical Dosage Form Containing Tetrahydrobiopterin
EP2562176B1 (en) 2010-04-22 2018-08-15 Nihon University Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CA2828685C (en) 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
IN2014DN09053A (https=) 2012-05-07 2015-05-22 Shiratori Pharm
US10365267B2 (en) 2014-10-31 2019-07-30 Children's Medical Center Corporation Methods and assays relating to sepiapterin reductase inhibition
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
US11072614B2 (en) * 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
CN112654356A (zh) 2018-05-30 2021-04-13 Ptc医疗Mp公司 增加四氢生物蝶呤血浆暴露的组合物和方法
AU2019277372B2 (en) * 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
EP3801536B1 (en) 2018-05-30 2024-07-17 PTC Therapeutics MP, Inc. Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Similar Documents

Publication Publication Date Title
JP2021525746A5 (https=)
TW576743B (en) Extended release formulations of erythromycin derivatives
JP5671560B2 (ja) 固体投与形中のテトラサイクリン金属錯体
CA2703971C (en) Stabilized pediatric suspension of carisbamate
TWI522100B (zh) 含有納布啡（ｎａｌｂｕｐｈｉｎｅ）之藥學組成物及其用途
JP6209495B2 (ja) 上部消化管治療用医薬製剤
JP2024069192A5 (https=)
JP2021525729A5 (https=)
CN103298464A (zh) 复方组合物
JP2007509146A (ja) レボドーパの持続効果のための組成物及び投与形
WO2011136751A2 (en) Water soluble pharmaceutical composition
JPWO2019232126A5 (https=)
EP3236949B1 (en) Product based on iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, formulations thereof, and pharmaceutical uses thereof
JPWO2019232130A5 (https=)
JP2007530692A (ja) ６−メルカプトプリンの改良された製剤
WO2013006146A1 (en) Effervescent formulations comprising dexketoprofen
EP4543414A1 (en) An orodispersible pharmaceutical composition of baclofen and its process of preparation
WO2025023901A1 (en) The pharmaceutical combination comprising phosphodiesterase type-5 inhibitor and l-arginine
JP7738832B2 (ja) 低亜鉛血症治療剤
WO2018185669A1 (en) Effervescent compositions comprising saxagliptin or salt thereof
JP5977672B2 (ja) イブプロフェンリシナートの経口投与用の懸濁液
JPH059116A (ja) ３−オキシゲルミルプロピオン酸組成物並びに該組成物を主成分とする細胞変性抑制剤
ES2731598T3 (es) Formulación pediátrica que comprende ácido biliar
WO2025023902A1 (en) The pharmaceutical combination comprising phosphodiesterase type-5 inhibitor, l-arginine and panax ginseng
CN120936353A (zh) 控释pde10a制剂